Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.34 |
| ▸ | SKP1 | P63208 | 1/20 | 0.34 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14878683 | 0.79 | USP2 (0.39) | HPGDGPR119MEN1KMT2AESR2 | |
| SCHEMBL7899134 | 0.78 | USP2 (0.38) | HPGDGPR119MEN1KMT2AESR2 | |
| SCHEMBL31555840 | 0.75 | ESR2 (0.39) | HPGDGPR119MEN1KMT2AESR2 | |
| SCHEMBL16583210 | 0.75 | USP2 (0.39) | HPGDGPR119MEN1KMT2AESR2 | |
| SCHEMBL24710864 | 0.74 | HRH3 (0.36) | HPGDGPR119MAPT | |
| SCHEMBL24710878 | 0.74 | GRM5 (0.33) | GPR119MEN1KMT2AESR2LMNA | |
| SCHEMBL24711551 | 0.74 | GPR119 (0.37) | HPGDGPR119KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL24710633 | 0.74 | GPR119 (0.34) | GPR119MAPTBTK | |
| SCHEMBL24710459 | 0.74 | NPBWR1 (0.36) | GPR119MEN1KMT2ABTK | |
| SCHEMBL21258531 | 0.73 | BTK (0.36) | HPGDGPR119MEN1KMT2AESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104530088-A | Tert-butyl 2-amino-6,7-dihydro-5H-thiazolo[5,4-b]pyridyl-4-carboxylate and derivatives thereof, and their synthesis method | SUZHOU SHIYA BIOPHARMACEUTICALS INC | 2015-04-22 | — | — | CN | claimed |
| US-20230331720-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | OXFORD FINANCE LLC | 2023-10-19 | — | — | US | disclosed |
| US-20230331720-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | OXFORD FINANCE LLC | 2023-10-19 | — | — | US | disclosed |
| EP-4208465-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | Orexia Therapeutics Limited (GB) | 2023-07-12 | — | — | EP | disclosed |
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2023113534-A1 | METHOD FOR PREPARATION OF (2R, 3S)-2-(BENZO[D]IMIDAZOLYLPROPYL)PIPERIDIN-3-OL DERIVATIVES | 주식회사 대웅제약 | 2023-06-22 | — | — | WO | disclosed |
| EP-4069366-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| WO-2022051583-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | OREXIA THERAPEUTICS LIMITED (GB) | 2022-03-10 | — | — | WO | disclosed |
| CN-104530088-A | Tert-butyl 2-amino-6,7-dihydro-5H-thiazolo[5,4-b]pyridyl-4-carboxylate and derivatives thereof, and their synthesis method | SUZHOU SHIYA BIOPHARMACEUTICALS INC | 2015-04-22 | — | — | CN | disclosed |
| US-8642587-B2 | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8642587-B2 | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8642587-B2 | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-02-04 | — | — | US | disclosed |
| EP-2396323-A1 | Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1 | Abbott GmbH & Co. KG (DE) | 2011-12-21 | — | — | EP | disclosed |
| US-20110009378-A1 | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy | ABBOTT GMBH & CO. KG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009378-A1 | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy | ABBOTT GMBH & CO. KG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009378-A1 | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy | ABBOTT GMBH & CO. KG (DE) | 2011-01-13 | — | — | US | disclosed |
| WO-2010092181-A1 | HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | ABBOTT GMBH & CO. KG (DE) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010092181-A1 | HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | ABBOTT GMBH & CO. KG (DE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009378-A1 | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy | CYP11B2, CYP11B1, SLC10A1 | HPGD 11/4885GPR119 722/4885MEN1 365/4885 |
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | ATM, CHEK2, CHEK1 | HPGD 2657/4885GPR119 3204/4885MEN1 1920/4885 |
| US-20230331720-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | HCRTR2, HCRTR1, CRHR2 | HPGD 2025/4885GPR119 6/4885MEN1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.